Research ArticleClinical Studies
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI and RYOICHI IMAMURA
Anticancer Research June 2025, 45 (6) 2563-2573; DOI: https://doi.org/10.21873/anticanres.17628
TOMOHIRO MATSUO
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
YASUYOSHI MIYATA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
JUNKI HARADA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
ITSUHO ITOH
2Department of Urology, Sasebo City General Medical Center, Sasebo, Nagasaki, Japan;
3Department of Urology, Nagasaki Harbor Medical Center, Nagasaki, Japan;
TSUYOSHI MATSUDA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
AKIHIRO ASAI
4Department of Urology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan;
TSUBASA KONDO
5Department of Urology, National Hospital Organization Ureshino Medical Center, Saga, Japan;
HIROKI KURATA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
6Department of Urology, National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan;
SUZUNA SAKAI
7Department of Urology, Japan Community Health Care Organization, Isahaya General Hospital, Nagasaki, Japan
HIDENORI ITOH
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
KENSUKE MITSUNARI
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;
RYOICHI IMAMURA
1Department of Urology, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki, Japan;

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
patientACCESS
patientACCESS - Patients desiring access to articles
In this issue
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI, RYOICHI IMAMURA
Anticancer Research Jun 2025, 45 (6) 2563-2573; DOI: 10.21873/anticanres.17628
Efficacy of Pembrolizumab as Second or Third-line Therapy for Local Advanced and Metastatic Urothelial Cancer
TOMOHIRO MATSUO, YASUYOSHI MIYATA, JUNKI HARADA, ITSUHO ITOH, TSUYOSHI MATSUDA, AKIHIRO ASAI, TSUBASA KONDO, HIROKI KURATA, SUZUNA SAKAI, HIDENORI ITOH, KENSUKE MITSUNARI, RYOICHI IMAMURA
Anticancer Research Jun 2025, 45 (6) 2563-2573; DOI: 10.21873/anticanres.17628





